Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections

Forty patients with urinary tract infections were randomly assigned to receive a ten-day course of oral therapy with either norfloxacin 400 mg twice daily or cotrimoxazole (trimethoprim-sulfamethoxazole) 160/800 mg twice daily. There were 34 cases (19 in the norfloxacin and 15 in the cotrimoxazole g...

Full description

Saved in:
Bibliographic Details
Published in:European Journal of Clinical Microbiology 1983-06, Vol.2 (3), p.260-265
Main Authors: Guerra, J G, Falconi, E, Palomino, J C, Benavente, L, Antunez de Mayolo, E
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anti-Bacterial Agents - therapeutic use
Anti-Infective Agents, Urinary - therapeutic use
Bacteria - drug effects
Clinical Trials as Topic
Drug Combinations - therapeutic use
Female
Humans
Male
Middle Aged
Nalidixic Acid - analogs & derivatives
Nalidixic Acid - therapeutic use
Norfloxacin
Sulfamethoxazole - therapeutic use
Trimethoprim - therapeutic use
Trimethoprim, Sulfamethoxazole Drug Combination
Urinary Tract Infections - drug therapy
Urinary Tract Infections - microbiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty patients with urinary tract infections were randomly assigned to receive a ten-day course of oral therapy with either norfloxacin 400 mg twice daily or cotrimoxazole (trimethoprim-sulfamethoxazole) 160/800 mg twice daily. There were 34 cases (19 in the norfloxacin and 15 in the cotrimoxazole group) of evaluable infections due to Escherichia coli (85% of cases), Klebsiella pneumoniae, Enterobacter spp., Proteus vulgaris and Alcaligenes faecalis. All organisms were sensitive to the assigned study drug. Twenty-two strains of Escherichia coli and five other isolates had a norfloxacin MIC50 of 0.03 mg/l and MIC90 of 1.0 mg/l. All patients were cured of the initial infection. Three diabetic patients in the norfloxacin group and another healthy patient in the cotrimoxazole group experienced asymptomatic recurrences due to organisms of the same species which, in the absence of causes of bacterial persistence, were considered to be reinfections. Mild reversible adverse effects of no clinical significance were observed in nine patients in each treatment group. Norfloxacin seems to be as effective and safe as cotrimoxazole in the conventional treatment of uncomplicated urinary tract infection.
ISSN:0722-2211
1435-4373
DOI:10.1007/BF02029529